Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Neurolief Secures Single Case Agreements with U.S. Payers for Proliv®Rx At-Home Depression Therapy


      News provided by

      Neurolief Inc.

      Nov 18, 2026, 08:30 ET

      Share this article

      Share this article


      Company accepting prescriptions from all clinicians whose patients are seeking insurance coverage, marking a key milestone toward broader payer access

      CORAL SPRINGS, Fla., Nov. 18, 2026 /PRNewswire/ -- Neurolief today announced that it has secured single case agreements with U.S. payers for Proliv®Rx, its FDA-approved at-home brain neuromodulation therapy for adults with major depressive disorder (MDD) who have not achieved satisfactory improvement from at least one antidepressant medication. With a commercial reimbursement pathway now in place, the company is accepting prescriptions from all clinicians whose patients are seeking insurance coverage.

      Effective Physician Supervised 16-Week Depression Treatment
      Effective Physician Supervised 16-Week Depression Treatment
      FDA Approved At-Home Depression Treatment
      FDA Approved At-Home Depression Treatment
      External Combined Occipital and Trigeminal Afferent Stimulation
      External Combined Occipital and Trigeminal Afferent Stimulation

      Under a single case agreement, an insurer agrees to cover a specific treatment for an individual patient when the treatment is considered medically necessary, giving patients a way to access novel therapies that are not yet part of a health plan's standard coverage policy.

      "Securing single case agreements with U.S. payers is an important milestone in our strategy to expand access to Proliv Rx," said Scott Drees, CEO of Neurolief. "It shows there is a viable path to commercial reimbursement, and we want to make that path as simple as possible for patients and their clinicians.

      "Our team works directly with the providers and the payers on each patient's behalf, from documenting medical necessity and submitting prior authorization requests to supporting appeals if a request is denied," continued Drees. "Together with FDA approval and strong clinical outcomes, this brings us closer to reaching the many patients who have not found adequate relief with antidepressants alone."

      Proliv Rx is delivered through a structured, physician-supervised program of 8 to 16 weeks, with two 40-minute sessions a day completed at home. A connected digital platform supports remote oversight, onboarding, adherence monitoring and symptom tracking.

      "For patients who do not respond adequately to antidepressants, accessing advanced treatment used to require repeated visits to specialized treatment centers," said Owen Muir, M.D., chief medical officer of Neurolief. "Proliv Rx brings clinically validated therapy into the home under physician supervision. Expanding reimbursement turns breakthrough innovation into real-world access. This offers hope to patients who might otherwise continue to struggle despite standard-of-care approaches. Our payer partners recognize the difference this therapy can make based on the strength of our clinical data."

      The reimbursement milestone builds on the FDA approval of Proliv Rx and compelling clinical results from the pivotal MOOD study, a randomized, double-blind, sham-controlled, multicenter trial involving 124 adults with MDD who continued to experience significant symptoms despite antidepressant treatment. Remission was more than three times as common with active treatment as with sham at eight weeks (21.3% vs. 6.0%) and reached 31.7% after 16 weeks of active treatment. Among patients receiving active treatment, the proportion with severe or very severe depression fell from 81% at baseline to just 15% after 16 weeks, while the proportion with mild or no depression increased from 0% to 56%.

      An estimated 21 million U.S. adults had at least one major depressive episode in the past year, according to the National Institute of Mental Health, and about one-third of people with MDD do not achieve an adequate response to antidepressant treatment. Advanced options such as transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and esketamine require repeated in-clinic visits, creating barriers for many patients, especially in rural and underserved areas.

      Neurolief is pursuing a broader market-access strategy across commercial payers, health systems and the U.S. Department of Veterans Affairs (VA) to expand access to Proliv Rx.

      About Proliv Rx

      Proliv Rx is an FDA-approved prescription at-home brain neuromodulation therapy for adults with MDD who have not achieved an adequate response to at least one antidepressant medication. Based on External Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS), the non-invasive therapy uses three independent stimulation channels and six electrodes to stimulate branches of the occipital and trigeminal nerves across the forehead and back of the head, sending signals to brain networks involved in mood regulation without penetrating the skull. The treatment is prescribed and managed under physician supervision and self-administered by the patient at home, supported by a digital platform for remote monitoring.

      About Neurolief

      Neurolief is developing neuromodulation therapies for mental health and neurological disorders. The company is focused on bridging critical gaps in medical care by delivering clinically validated treatments that pair scientific rigor with scalable, real-world accessibility.

      SOURCE Neurolief Inc.

      Modal title

      Also from this source

      Neurolief Expands Veterans' Access to Prescription Neuromodulation for Depression and Migraine Through New VA Contract

      Neurolief Expands Veterans' Access to Prescription Neuromodulation for Depression and Migraine Through New VA Contract

      Neurolief, a neuroscience-driven medical technology company developing brain neuromodulation therapies for mental health and neurological conditions, ...

      Neurolief to Showcase Proliv®Rx at APA 2026, Highlighting FDA-Approved, Physician-Directed At-Home Brain Stimulation for Major Depressive Disorder

      Neurolief to Showcase Proliv®Rx at APA 2026, Highlighting FDA-Approved, Physician-Directed At-Home Brain Stimulation for Major Depressive Disorder

      Neurolief, Inc., a medical technology company developing noninvasive neuromodulation therapies for mental health and neurological conditions, today...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Mental Health

      Mental Health

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      New Products & Services

      New Products & Services

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.